International Journal of Contemporary Pediatrics,
Journal Year:
2023,
Volume and Issue:
10(12), P. 1876 - 1880
Published: Nov. 4, 2023
Atopic
dermatitis
is
a
prominent
dermatological
condition
in
children
that
frequently
affects
their
lifestyle.
Conventional
treatments
prove
inadequate,
necessitating
the
use
of
biological
agents
like
Lebrikizumab
to
address
at
its
core
pathophysiological
level.
The
introduction
biologic
drugs
has
broadened
spectrum
treatment
options
for
patients
with
moderate
severe
atopic
dermatitis,
especially
those
who
have
not
achieved
satisfactory
results
conventional
monotherapy
or
combination
therapies,
contraindications
systemic
immunosuppressive
agents.
appears
be
promising
option
showing
strong
response
clinical
trials.
It
offers
potential
improved
long-term
efficacy
and
reduction
adverse
effects.
This
article
provides
an
overview
Lebrikizumab's
role
addressing
pathogenesis
highlights
current
advancements.
Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research,
Journal Year:
2023,
Volume and Issue:
unknown, P. 439 - 447
Published: Oct. 10, 2023
Translational
bioinformatics
has
been
a
new
science
that
uses
to
transform
huge
volumes
of
molecular
targets
into
therapeutic
therapies.The
bioinformatical
approach
pinpoints
better
understanding
disease
processes
by
combining
genetic,
phenomic,
and
environmental
data.Our
summary
integrates
several
explanations
from
diverse
publications
were
combined
construct
pathways
depict
the
expression
gene
mutations
in
driving
variety
diseases.The
study
involves
literatures
indexed
Scopus
Pub
Med,
search
combination
following
keyword
variants;
"HaploReg"
AND
"genomic",
"repurposing
drug".This
only
used
original
articles
English
which
peer
reviewed
journals
published
2022.Thus,
screening
results
library
sources
narrowed
10
met
inclusion
criteria.Here
in,
we
list
16
genes
have
driven
nine
special
diseases,
two
(JAK,
CD207)
encode
atopic
dermatitis,
trigger
vitiligo
(IFIH1,
TICAM1),
role
multiple
sclerosis
(CD80,
CD86),
pathway
three
activate
ankylosing
spondylitis
(HLA-B27-ERAP1),
link
breast
cancer
(EMSY),
associate
with
gastric
(MMP-7),
relate
colorectal
(miR-143/145,
KRAS),
play
chronic
prostatitis/chronic
pelvic
pain
syndrome
(IFNG,
IFNGR1,
AR),
rule
on
arterial
hypertension
(TBX2).Last,
our
discovery
provides
insight
development
novel
medications
act
specific
druggable
target
not
previously
investigated.
International Journal of Contemporary Pediatrics,
Journal Year:
2023,
Volume and Issue:
10(12), P. 1876 - 1880
Published: Nov. 4, 2023
Atopic
dermatitis
is
a
prominent
dermatological
condition
in
children
that
frequently
affects
their
lifestyle.
Conventional
treatments
prove
inadequate,
necessitating
the
use
of
biological
agents
like
Lebrikizumab
to
address
at
its
core
pathophysiological
level.
The
introduction
biologic
drugs
has
broadened
spectrum
treatment
options
for
patients
with
moderate
severe
atopic
dermatitis,
especially
those
who
have
not
achieved
satisfactory
results
conventional
monotherapy
or
combination
therapies,
contraindications
systemic
immunosuppressive
agents.
appears
be
promising
option
showing
strong
response
clinical
trials.
It
offers
potential
improved
long-term
efficacy
and
reduction
adverse
effects.
This
article
provides
an
overview
Lebrikizumab's
role
addressing
pathogenesis
highlights
current
advancements.
